CK Life Sciences International Holdings's EBIT per Share for the
six
months ended in Dec. 2025 was $0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00.
During the past 12 months, the average EBIT per Share Growth Rate of CK Life Sciences International Holdings was -275.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of CK Life Sciences International Holdings was 116.50% per year. The lowest was -32.70% per year. And the median was -4.50% per year.
CKLSF's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15.5 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
CK Life Sciences International Holdings (OTCPK:CKLSF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
CK Life Sciences International Holdings EBIT per Share Related Terms
CK Life Sciences International Holdings EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CK Life Sciences International Holdings EBIT per Share Chart
CK Life Sciences International Holdings Annual Data
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CK Life Sciences International Holdings (CKLSF) has a EBIT per Share of $0.00 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on CK Life Sciences International Holdings and its competitors. According to the industry distribution chart, CK Life Sciences International Holdings ranks #999999 out of 1181 companies in the Biotechnology industry.
Is CK Life Sciences International Holdings' EBIT per Share too high?
CK Life Sciences International Holdings' current EBIT per Share is $0.00. Based on the distribution chart, CK Life Sciences International Holdings ranks #999999 out of 1181 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CK Life Sciences International Holdings has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does CK Life Sciences International Holdings' EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CK Life Sciences International Holdings ranks #999999 out of 1181 companies for EBIT per Share. This places CK Life Sciences International Holdings in the lower half of its industry. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,181 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on CK Life Sciences International Holdings and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CK Life Sciences International Holdings's current EBIT per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CK Life Sciences International Holdings stock overvalued right now?
CK Life Sciences International Holdings (CKLSF) has a current EBIT per Share of $0.00. The stock's GF Value™ is $0.11, compared to a current price of $0.09 — trading 18.2% below its estimated fair value. The current EBIT per Share is $0.00. CK Life Sciences International Holdings' overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For CK Life Sciences International Holdings (CKLSF), the current EBIT per Share is $0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CK Life Sciences International Holdings (CKLSF) Overvalued in 2026?
Based on GuruFocus' analysis, CK Life Sciences International Holdings stock appears to be undervalued.
The current stock price of $0.09 is trading 18.2% below its estimated GF Value™ of $0.11.
Key valuation signals for CKLSF:
EBIT per Share: $0.00
GF Value™: $0.11 vs. price of $0.09 (18.2% below fair value)
No single metric tells the full story. See the CKLSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CK Life Sciences International Holdings Business Description
CK Life Sciences International Holdings Inc is an international life sciences company. It is engaged in research and development, manufacturing, commercialization, marketing and selling of health and agriculture-related products, as well as investment in a portfolio of vineyards, and various financial and investment products. Its pipeline includes Seviprotimut-L, TTX-MC138, Seviprotimut-L + TTX-MC138, TTX-RIGA, Halneuron, among others. Its segments include Agriculture-related, Nutraceutical, and Pharmaceuticals & Diagnostics R&D with the majority of the revenue deriving from Nutraceutical segment. Geographically it operates in Asia Pacific that derives the majority of the revenue and North America.
34GF Score
Get the complete analysis for CKLSF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CKLSF has been successfully added to your 
